21

Addressing an Evolving Drug Safety Landscape - Moving from passive to active pharmacovigilance

Embed Size (px)

Citation preview

Page 1: Addressing an Evolving Drug Safety Landscape - Moving from passive to active pharmacovigilance
Page 2: Addressing an Evolving Drug Safety Landscape - Moving from passive to active pharmacovigilance

Page 3: Addressing an Evolving Drug Safety Landscape - Moving from passive to active pharmacovigilance

Page 4: Addressing an Evolving Drug Safety Landscape - Moving from passive to active pharmacovigilance

Page 5: Addressing an Evolving Drug Safety Landscape - Moving from passive to active pharmacovigilance

•0%

20%

40%

60%

80%

100%

Manufacturersubmitted -Expedited

reports

Manufacturersubmitted -

Periodicreports

Direct reportsby HCPs &

Patients

Incompletereports

Completereports

Page 6: Addressing an Evolving Drug Safety Landscape - Moving from passive to active pharmacovigilance
Page 7: Addressing an Evolving Drug Safety Landscape - Moving from passive to active pharmacovigilance

2% 3% 1%

11%

Page 8: Addressing an Evolving Drug Safety Landscape - Moving from passive to active pharmacovigilance

15%

5%

32%

4% 6%

5%

9%

12%

12%

Page 9: Addressing an Evolving Drug Safety Landscape - Moving from passive to active pharmacovigilance

Page 10: Addressing an Evolving Drug Safety Landscape - Moving from passive to active pharmacovigilance
Page 11: Addressing an Evolving Drug Safety Landscape - Moving from passive to active pharmacovigilance

.

Page 12: Addressing an Evolving Drug Safety Landscape - Moving from passive to active pharmacovigilance
Page 13: Addressing an Evolving Drug Safety Landscape - Moving from passive to active pharmacovigilance
Page 14: Addressing an Evolving Drug Safety Landscape - Moving from passive to active pharmacovigilance

Page 15: Addressing an Evolving Drug Safety Landscape - Moving from passive to active pharmacovigilance
Page 16: Addressing an Evolving Drug Safety Landscape - Moving from passive to active pharmacovigilance
Page 17: Addressing an Evolving Drug Safety Landscape - Moving from passive to active pharmacovigilance

Page 18: Addressing an Evolving Drug Safety Landscape - Moving from passive to active pharmacovigilance

Page 19: Addressing an Evolving Drug Safety Landscape - Moving from passive to active pharmacovigilance

Page 20: Addressing an Evolving Drug Safety Landscape - Moving from passive to active pharmacovigilance